Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2015Título de revista
Arthritis and Rheumatology
Tipo de contenido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)